Skip to content

Study · Animal study (in vivo) · guinea pig · 1995

5 results

Consistent GH responses to repeated injection of GH-releasing hexapeptide (GHRP-6) and the non-peptide GH secretagogue, L-692,585.

Fairhall KM, Mynett A, Smith RG, Robinson IC

The Journal of endocrinology1 Jun 1995Cited by 18 (Europe PMC)

PMID7636426 (opens in a new tab)DOI10.1677/joe.0.1450417 (opens in a new tab)PepBankPUB-07636426
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Activity measurement

    In conscious guinea pigs, GHRP‑6 was approximately tenfold more potent than L-692,585 for GH release.

    In plain wordsIn guinea pigs, GHRP‑6 was about ten times stronger than L-692,585 at releasing growth hormone.

    Peptide
    GHRP-6
    Outcome
    Not applicablePotency for GH release versus L-692,585
    Study

    guinea pign: not reported in source

    Chronically cannulated conscious guinea pigs
    Comparator
    L-692,585
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    L-692,585 was approximately tenfold less potent than GHRP-6 for GH release
    1 context sentence
    Summary · context
    We now compare the GH-releasing properties of GHRP-6 and a novel benzolactam GH secretagogue L-692,585 using chronically cannulated guinea pigs and automated blood micro-sampling to study the effects of repeated exposure to these secretagogues.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In conscious guinea pigs, serial GHRP‑6 injections at intervals of 60 or 90 min produced variable GH release with a cyclic pattern of responsiveness.

    In plain wordsIn guinea pigs, repeated GHRP‑6 injections at 60 or 90 minute intervals gave uneven growth hormone release that rose and fell in cycles.

    Peptide
    GHRP-6
    Outcome
    MixedGH release pattern after serial injections at 60 or 90 min
    Study

    guinea pign: not reported in source

    Chronically cannulated conscious guinea pigs
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Serial injections of GRF, GHRP-6 or L-692,585 at intervals of 60 or 90 min produced variable GH release which followed a cyclic pattern of responsiveness.
    1 context sentence
    Summary · context
    We now compare the GH-releasing properties of GHRP-6 and a novel benzolactam GH secretagogue L-692,585 using chronically cannulated guinea pigs and automated blood micro-sampling to study the effects of repeated exposure to these secretagogues.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In conscious guinea pigs, lengthening the interval between GHRP‑6 injections to 3 h produced more regular GH responses.

    In plain wordsIn guinea pigs, spacing GHRP‑6 injections 3 hours apart gave more regular growth hormone responses.

    Peptide
    GHRP-6
    Outcome
    IncreaseGH response regularity with 3 h pulse interval
    Study

    guinea pign: not reported in source

    Chronically cannulated conscious guinea pigs
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Prolonging the pulse interval to 3 h produced more regular responses to both GHRP-6 and L-692,585.
    1 context sentence
    Summary · context
    We now compare the GH-releasing properties of GHRP-6 and a novel benzolactam GH secretagogue L-692,585 using chronically cannulated guinea pigs and automated blood micro-sampling to study the effects of repeated exposure to these secretagogues.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In conscious guinea pigs, continuous intravenous infusion of low doses of GHRP‑6 elicited an initial GH release.

    In plain wordsIn guinea pigs, a slow continuous low-dose GHRP‑6 infusion first triggered a release of growth hormone.

    Peptide
    GHRP-6
    Outcome
    IncreaseInitial GH release during continuous infusion
    Study

    guinea pign: not reported in source

    Chronically cannulated conscious guinea pigs
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    low doses · intravenousAs given in this study (guinea pig).

    Source sentences

    Summary
    Continuous i.v. infusion of low doses of either secretagogue elicited an initial GH release
    1 context sentence
    Summary · context
    We now compare the GH-releasing properties of GHRP-6 and a novel benzolactam GH secretagogue L-692,585 using chronically cannulated guinea pigs and automated blood micro-sampling to study the effects of repeated exposure to these secretagogues.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In conscious guinea pigs, continuous intravenous infusion of low doses of GHRP‑6 amplified the spontaneous GH secretory pattern over the next 6 h.

    In plain wordsIn guinea pigs, a slow continuous low-dose GHRP‑6 infusion boosted the animal's own growth hormone rhythm over the next 6 hours.

    Peptide
    GHRP-6
    Outcome
    IncreaseSpontaneous GH secretory pattern during continuous infusion
    Study

    guinea pign: not reported in source

    Chronically cannulated conscious guinea pigs
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    low doses · intravenous · next 6 hAs given in this study (guinea pig).

    Source sentences

    Summary
    Continuous i.v. infusion of low doses of either secretagogue elicited an initial GH release, and amplified the spontaneous GH secretory pattern over the next 6 h.
    1 context sentence
    Summary · context
    We now compare the GH-releasing properties of GHRP-6 and a novel benzolactam GH secretagogue L-692,585 using chronically cannulated guinea pigs and automated blood micro-sampling to study the effects of repeated exposure to these secretagogues.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.